|
Influence of liposomal irinotecan (nal-IRI) and non-liposomal irinotecan, alone and in combination, on tumor growth and angiogenesis in colorectal cancer (CRC) models. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Ipsen; Merrimack |
Patents, Royalties, Other Intellectual Property - Merrimack (Inst) |
|
|
Employment - Scholar Rock |
Stock and Other Ownership Interests - Scholar Rock |
Patents, Royalties, Other Intellectual Property - Scholar Rock |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Lilly; Roche; Sanofi |
Travel, Accommodations, Expenses - Amgen; Merck; Roche; Sanofi |
|
|
Honoraria - Chugai Pharma; Yakult Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |